Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women.
about
Lack of bone neoplasms and persistence of bone efficacy in cynomolgus macaques after long-term treatment with teriparatide [rhPTH(1-34)].The effects of excipients and particle engineering on the biophysical stability and aerosol performance of parathyroid hormone (1-34) prepared as a dry powder for inhalationEffect of Sequential Treatment with Bisphosphonates After Teriparatide in Ovariectomized Rats: A Direct Comparison Between Risedronate and Alendronate.Parathyroid hormone treatment increases fixation of orthopedic implants with gap healing: a biomechanical and histomorphometric canine study of porous coated titanium alloy implants in cancellous bone.Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidismHormonal therapies and osteoporosis.A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.Intermittent Administration of Parathyroid Hormone [1-34] Prevents Particle-Induced Periprosthetic Osteolysis in a Rat Model.Systemic intermittent parathyroid hormone treatment improves osseointegration of press-fit inserted implants in cancellous boneEffect of TheraCyte-encapsulated parathyroid cells on lumbar fusion in a rat modelCancer treatment-related bone loss: a review and synthesis of the literature.Enhancement of fracture healing with parathyroid hormone: preclinical studies and potential clinical applications.PTH prevents the adverse effects of focal radiation on bone architecture in young ratsThe combined effect of parathyroid hormone and bone graft on implant fixation.Activation of the acquired immune response reduces coupled bone formation in response to a periodontal pathogen.Parathyroid hormone reverses radiation induced hypovascularity in a murine model of distraction osteogenesis.PTH(1-34) replacement therapy in a child with hypoparathyroidism caused by a sporadic calcium receptor mutation.Teriparatide and the treatment of bisphosphonate-related osteonecrosis of the jaw: a rat model.Parathyroid hormone analogues in the treatment of osteoporosis.Parathyroid hormone and its effects on dental tissues.High-throughput in vivo screening for bone anabolic compounds with zebrafish.Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose.Parathyroid hormone (1-34) compensates the negative effect of smoking around implants.Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone (1-34) administration.Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing.Effect of high-frequency loading and parathyroid hormone administration on peri-implant bone healing and osseointegration.Treatment of osteoporosis in men
P2860
Q33358285-362ED8A3-57E0-4059-86D0-3699CC273587Q33805046-A086522E-5C63-4D79-BDD5-B67C19E9DCA8Q33841863-25E31FCB-3CBB-49DF-A20A-7972497680E0Q34690479-B645037F-E3E2-412A-89C9-EA9B73051B85Q35744474-3544BF0D-7F0D-4A20-895C-07EB347A6DC2Q35757566-A890D347-9165-4945-8E45-3E91DC4AEA56Q35779222-61C7F053-E7FA-438A-B622-E5E431D066C9Q36127944-0283A3BE-3233-4CD7-8DF1-A3302923867FQ36189014-DCD8288C-E760-4A99-B37C-A5A3C4E7A288Q36282080-91635BF6-6A43-463E-89B8-F63B542710AAQ36410640-13CCA3EA-2B15-419F-8A3D-63A459B3409FQ36764005-632BE0AE-8DCE-4379-AE17-365F4C2D9AB9Q36920155-72606916-758D-48ED-9C4E-17BD04F46A63Q36926814-E3B92800-AAD2-4EAD-BF8E-4F0A1143FBD7Q37089072-84AF7A0D-3FCF-418D-8899-A423FCED99BDQ37134482-B68B689B-C386-422F-8C7C-54A07A4DE465Q37166823-69CFAB44-1293-4031-AD16-C7B62C45B90FQ37460461-1F1810AB-6903-43C3-A3F1-F926BDF8674EQ37900475-4B849C5C-1E27-4957-B19D-2E399050BAF9Q37927181-2F9E1047-54F0-4974-AD6F-5633478D4CC9Q40380121-9B41370C-4FD9-43A0-BF47-51F8B7059C86Q47325378-7AC5A633-9018-41E1-BA07-67FE23DC9651Q47603053-46937BFC-3069-4FAF-9507-796A24AA3BC5Q47962287-8CD8303F-694C-40ED-A398-3762D6137E6BQ53669998-43721ADA-ED14-4B81-B512-92D96D8E6A2FQ55280231-3CF32D94-4A1A-46D1-9854-3185954ED755Q56109539-F2A5C7E6-C7D5-48BE-9EB6-7247DBD77B83
P2860
Commentary on clinical safety of recombinant human parathyroid hormone 1-34 in the treatment of osteoporosis in men and postmenopausal women.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Commentary on clinical safety ...... men and postmenopausal women.
@ast
Commentary on clinical safety ...... men and postmenopausal women.
@en
Commentary on clinical safety ...... men and postmenopausal women.
@nl
type
label
Commentary on clinical safety ...... men and postmenopausal women.
@ast
Commentary on clinical safety ...... men and postmenopausal women.
@en
Commentary on clinical safety ...... men and postmenopausal women.
@nl
prefLabel
Commentary on clinical safety ...... men and postmenopausal women.
@ast
Commentary on clinical safety ...... men and postmenopausal women.
@en
Commentary on clinical safety ...... men and postmenopausal women.
@nl
P1476
Commentary on clinical safety ...... men and postmenopausal women.
@en
P2093
Armen H Tashjian
Bruce A Chabner
P304
P356
10.1359/JBMR.2002.17.7.1151
P577
2002-07-01T00:00:00Z